WallStSmart

Bionano Genomics Inc (BNGO)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 10925% more annual revenue ($3.33B vs $30.18M). WST leads profitability with a 17.0% profit margin vs -106.6%. WST earns a higher WallStSmart Score of 61/100 (C+).

BNGO

Hold

39

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -13.19

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BNGO.

WSTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$168.33

Current Price

$346.23

$177.90 premium

UndervaluedFair: $168.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNGO3 strengths · Avg: 9.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
21.4%8/10

Revenue surging 21.4% year-over-year

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

BNGO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.37M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-84.3%2/10

ROE of -84.3% — below average capital efficiency

Free Cash FlowQuality
$-4.67M2/10

Negative free cash flow — burning cash

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
2.672/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BNGO

The strongest argument for BNGO centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : BNGO

The primary concerns for BNGO are EPS Growth, Market Cap, Return on Equity.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

BNGO profiles as a growth stock while WST is a mature play — different risk/reward profiles.

BNGO carries more volatility with a beta of 1.65 — expect wider price swings.

BNGO is growing revenue faster at 21.4% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 39/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bionano Genomics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?